Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Taiga Biotechnologies Inc.

This article was originally published in Start Up

Executive Summary

The founders of Taiga Biotechnologies Inc. believe they can draw on the depth of their understanding about stem cells and gene manipulation to produce a variety of valuable medicines - from antibodies against cancer and infectious disease to therapeutic and prophylactic vaccines, even red blood cells that could provide a universal-donor source. It is not the first company intent on transferring modified stem cells into mice to produce human antibodies. But Taiga says it has found a way to override certain mechanics of the mouse immune system and ramp up production of antibodies that otherwise could not be made.
Advertisement

Related Content

Start-Up Previews (12/2010)
Start-Up Previews (12/2010)

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC091915

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel